Patient randomisations
0
Patient randomisations with suspected or proven COVID-19
0
Available interventions in 10 domains
0
Total patients
0
Patients with suspected or proven COVID-19
0
Active sites in Europe
EU numbers – updated 20-Mar-2023

REMAP-CAP
A Randomised, Embedded, Multi-factorial, Adaptive Platform trial
for Community-Acquired Pneumonia
The study
The Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) was conceived after the 2009 Influenza AH1N1 (“Swine flu”) outbreak. During that pandemic and previous ones, the research response has been largely absent. REMAP-CAP was set up as an Adaptive Platform Trial embedded in clinical care that allows multiple therapies to be evaluated at the same time under a master protocol. In Europe, the trial is currently running in 15 countries.
